Prescription-drug policy: Remove obstacles keeping alternatives from reaching the market

We’ve focused in the first two posts of this three-part series addressing prescription-drug policy (here and here) on proposals in the United States Senate which offer solutions in search of problems, harm competition and allow brand-name drug companies to continue keep life-saving generics off the market for longer periods of time – all  with costly…

Prescription-drug policy: Don’t throw the bed out with bedpan

According to IQVIA, a health-care data firm, generic prescription drugs saved Kentucky $5.7 billion in 2017, $3.2 billion of which were savings reaped by the commonwealth’s Medicare and Medicaid programs. However, legislation (S. 64) being considered by the U.S. Senate would delay Kentucky patients access the more-affordable generic and biosimilar drugs being developed today. In…

Prescription-drug policy: Don’t give the FDA power over standards for biosimilar medicine

While Kentucky Senator and Majority Leader Mitch McConnell’s proposal to raise the legal age of purchasing tobacco has received a large share of attention regarding the suite of healthcare proposals currently being considered in the U.S. Senate, other issues affecting cost and access to health care – including for prescription drugs – must be carefully…

PAUSE Act a responsible approach toward reforming the 340B drug pricing program

With 340B being back in the news and with beneficial legislation in the works, I wanted to take the opportunity to reshare my thoughts. The 340B program, a well-intentioned program which, through bureaucratic tinkering, has gone off the rails, primarily due to a lack of oversight and transparency, is back in the news. Created in…